Input 2021.01.27 13:42 | Revision 2021.01.27 13:44
Won Hee-mok, chairman of the Korea Pharmaceutical Bio Association, said at the New Year’s press conference held online on the 27th, “Please ask the government to implement a policy that connects innovation in the pharmaceutical bio industry to growth.”
In order to establish a mid- to long-term health industry promotion strategy that supports global environmental change and support, it is necessary to have a command tower that oversees the full-cycle policy from’basic research to completion of clinical trials’.
Chairman Won said, “Because the biohealth industry is a growth engine that will lead the national economy in the future, it is necessary to harmonize the regulatory policy and the fostering policy.” It must be accompanied by expansion,” he said.
Chairman Won said, “The solution to end the national crisis amid the Corona 19 pandemic is the development of treatments and vaccines.” “The era of realization of pharmaceutical sovereignty and global success” is a contemporary task and a reason for existence given to the Korean pharmaceutical bio industry in 2021. “We are committed to implementing four major tasks such as strengthening health and security, creating blockbusters, accelerating global advancement, and innovation in the industrial environment. I will do my best.” The idea is to put all of our capabilities into opening the era of success of’K-PHARM’ on the global stage.
He said that this year, it should be a turning point in the establishment of pharmaceutical sovereignty by deriving the results of the development of COVID-19 treatment and vaccine. Chairman Won said, “At least three new drugs are expected to be born this year. We will promote the expansion of the scope and scale of research and development at the national level to develop and produce COVID-19 vaccines and treatments on our own.
In Korea, GC Green Cross, Celltrion, Daewoong Pharmaceutical, and Chong Kun Dang are speeding up the development of COVID-19 treatments. SK Bioscience, Hanmi Pharmaceutical, GC Green Cross, and Samsung Biologics are planning to consign Corona 19 vaccines or have production capabilities.
Chairman Won said, “We will strengthen communication between the Korea Centers for Disease Control and Prevention, which is an infectious disease control tower, and the industry to resolve difficulties in the field,” he said. Requested on.
The plan is to establish a stable supply system, such as increasing the self-sufficiency rate of domestic drug substances. Considering that the raw material drug self-sufficiency rate is the record low (16%), 200 ingredients that are urgently localized out of the 2,000 raw materials are selected and focused on fostering the drug substance so that the self-sufficiency rate can be raised to the level of 50% after five years. It is a compound plan to promote.
They also decided to concentrate on creating new blockbuster drugs. It intends to create a global success model based on R&D selection and concentration, scale expansion through mergers and acquisitions, and blockbuster creation. It also decided to promote open innovation and the development of convergence and advanced drugs.
In order to accelerate global advancement, the association plans to install and operate the Hankuk Pharmaceutical Bio Innovation Center (tentative name KPBIC) in Boston, USA, and promote the establishment of a second KPBIC in EU base countries. It decided to spur global open innovation by participating in the MIT Industry-Academic Cooperation Program (ILP) consortium in the US and joining the global collaboration program linked to the UK Life Science Research Institute. It also plans to support the expansion of emerging markets by domestic companies.
Chairman Won said to the government, “In order for the innovative challenges of the industry, such as convergence and the development of cutting-edge biopharmaceuticals, to blossom, we must make a rational change in line with the’regulatory science’ that has a decisive influence on the industry. He also ordered to advance regulations so that investment expansion and strategic alliances can be actively progressed through sufficient value compensation.